Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads your gut scans to spot disease without a scope

NCT ID NCT07087418

Diagnosis Sponsor: First Affiliated Hospital, Sun Yat-Sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is developing an artificial intelligence system that analyzes CT and MRI scans to diagnose and predict outcomes for digestive diseases like Crohn's disease, ulcerative colitis, and intestinal tuberculosis. Researchers are using data from 21 hospitals in China to train the AI, and will test it in two additional hospitals. The goal is to create a noninvasive tool that could reduce the need for colonoscopies and help doctors make faster, more accurate decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI diagnostic model using CT and MR imaging
What this could lead to
If successful, this could provide a noninvasive way to diagnose and predict the course of digestive diseases, potentially reducing the need for colonoscopies.
What could go wrong
This is an observational study, not a treatment trial. The AI model may not perform as well in real-world settings or in different populations, and it is still being tested for accuracy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This retrospective and prospective study included patients with digestive diseases. For the retrospective component, the investigators enrolled patients from 21 hospitals across China, including the First Affiliated Hospital of Sun Yat-sen University. For the prospective component, the investigators enrolled patients from the First Affiliated Hospital of Sun Yat-sen University and the Third Affiliated Hospital of Guangzhou Medical University.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with multimodal-confirmed diagnoses (clinical, imaging, endoscopic, and pathological) of: * Inflammatory bowel disease (IBD; Crohn's disease or ulcerative colitis) * Intestinal tuberculosis * Behçet's disease * Availability of ≥1 technically adequate CT or MR scan with high-quality colonoscopy performed within ±1 month of imaging. Exclusion Criteria: * ・Suboptimal imaging quality (e.g., low-dose artifacts, metal artifacts) * Inadequate bowel preparation for endoscopy * Incomplete examinations due to poor tolerance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ai (artificial intelligence) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Behcet disease Crohn disease Digestive System Diseases digestive system disorder intestinal tuberculosis ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ai (artificial intelligence) Digestive diseases Imaging Radiology

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • XploreMET v3.0 system

    RECRUITING

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.